Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Depression drug trial halted early – what we know

NCT ID NCT06011577

Symptom relief Sponsor: Levomecor Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tested a new drug called REL-1017 as an extra treatment for adults with major depression who didn't get enough help from standard antidepressants. The trial was stopped early and included only 27 participants. The main goal was to see if the drug could reduce depression symptoms over 28 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

27 people

The number who actually took part.

Started

Aug 2023

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Body mass index (BMI) between 18.0 and 35.0 kg/m2. * Diagnosed with Major Depressive Disorder (MDD) based on Structured Clinical Interview for DSM-5 (SCID-5) for MDD. * Inadequate response to 1 to 3 adequate antidepressant treatments in the current MDE. Exclusion Criteria: * Psychiatric hospitalization during the current major depressive episode. * History or presence of clinically significant health conditions which in the opinion of the Investigator would negatively impact the safety of the participant. * Participants who, in the Investigator's judgment, are at significant risk for suicide. * Pregnant or planning to become pregnant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression depressive disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression Major depressive disorder

Contacts and locations

Locations

  • Relmada Site

    Dothan, Alabama, 36303, United States

  • Relmada Site

    Homewood, Alabama, 35209, United States

  • Relmada Site

    Anaheim, California, 92805, United States

  • Relmada Site

    Lafayette, California, 94549, United States

  • Relmada Site

    Newport Beach, California, 92660, United States

  • Relmada Site

    Orange, California, 92868, United States

  • Relmada Site

    Redlands, California, 92374, United States

  • Relmada Site

    Sherman Oaks, California, 91403, United States

  • Relmada Site

    Farmington, Connecticut, 06030, United States

  • Relmada Site

    Brandon, Florida, 33511, United States

  • Relmada Site

    Hialeah, Florida, 33027, United States

  • Relmada Site

    Jacksonville, Florida, 32256, United States

  • Relmada Site

    Miami, Florida, 33133, United States

  • Relmada Site

    Miami, Florida, 33174, United States

  • Relmada Site

    Okeechobee, Florida, 34972, United States

  • Relmada Site

    Tampa, Florida, 33607, United States

  • Relmada Site

    Springfield, Illinois, 62794, United States

  • Relmada Site

    Baltimore, Maryland, 21208, United States

  • Relmada Site

    Mankato, Minnesota, 56001, United States

  • Relmada Site

    Toms River, New Jersey, 08755, United States

  • Relmada Site

    Brooklyn, New York, 11235, United States

  • Relmada Site

    Cedarhurst, New York, 11516, United States

  • Relmada Site

    New York, New York, 10036, United States

  • Relmada Site

    Philadelphia, Pennsylvania, 19104, United States

  • Relmada Site

    Franklin, Tennessee, 37067, United States

  • Relmada Site

    Memphis, Tennessee, 38119, United States

  • Relmada Site

    Austin, Texas, 78712, United States

  • Relmada Site

    Bellaire, Texas, 77401, United States

  • Relmada Site

    Friendswood, Texas, 77546, United States

  • Relmada Site

    Houston, Texas, 77030, United States

  • Relmada Site

    Wichita Falls, Texas, 76309, United States

  • Relmada Site

    Clinton, Utah, 84015, United States

  • Relmada Site

    Draper, Utah, 84020, United States

  • Relmada Site

    Rutland, Vermont, 05701, United States

  • Relmada Site

    Charlottesville, Virginia, 22903, United States

  • Relmada Site

    Seattle, Washington, 98104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.